Golimumab: A Phase 4, UK, Open Label, Single Arm Study on Its Utilization and Impact in Ulcerative Colitis
Phase of Trial: Phase IV
Latest Information Update: 17 Oct 2017
At a glance
- Drugs Golimumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms GO-COLITIS
- Sponsors Merck Sharp & Dohme
- 10 Jun 2017 Biomarkers information updated
- 26 May 2016 Status changed from active, no longer recruiting to completed.
- 28 Mar 2016 Planned primary completion date changed from 1 Mar 2016 to 1 May 2016 as reported by ClinicalTrials.gov record.